Video

Dr. Puri on Challenges With Treating Older Patients With Pancreatic Cancer

Akshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.

Akshjot Puri, MD, fellow, Houston Methodist Hospital, discusses challenges facing older patients with pancreatic cancer.

Most elderly patients with pancreatic cancer will have poor performance status due to age, comorbidities, renal failure, dementia, and cardiovascular disease, among others, explains Puri. The standard practice is to give these patients FOLFIRINOX as long as they have good performance status, says Puri.

Patients often experience infections and increased hematological adverse events (AEs), as well as non-hematological AEs, when given FOLFIRINOX as opposed to gemcitabine plus nab-paclitaxel (Abraxane) or gemcitabine alone, according to Puri. The treatment decision must account for the individual factors of each patient. If the patient is believed to be able to tolerate FOLFIRINOX, then that is the treatment of choice, Puri concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center